My Companies
Notification
Account
Log Out
Back

Mangalam Drugs Explores Sale of Vapi Unit-2 Contributing 32 Percent Revenue


18 November 2026
Mangalam Drugs And Organics Ltd.

Board approved exploring sale of leasehold land and building at Unit-2, Vapi and convening EGM for approval. Unit did Rs 74.46 Cr revenue, 32% of total. No buyer, price or timeline fixed. First asset-sale restructuring move while under lender enforcement and cash strain. Selling one of two Vapi units is a step change from pending merger plan and shrinks core malaria API base. Buyer, price, valuation, use of proceeds and scope whether plant ops included undisclosed. Needs EGM and regulatory nods plus lender stance; survival impact unclear.


Recent Events

Real time WhatsApp alerts using AI.

Get features of

  • Instant Notifications
  • Competitive Advantage
  • Critical Alerts
Signup or Sign in

Company Information